Functional ET(A)-ET(B) Receptor Cross-talk in Basilar Artery In Situ From ET(B) Receptor Deficient Rats.

J Cardiovasc Pharmacol

*Department of Cell Biology and Molecular Medicine, New Jersey Medical School, Rutgers University, Newark, NJ; †The Department of Pediatric Gastroenterology, The Ohio State University and Nationwide Children's Hospital Columbus, OH; ‡International Institute for Integrative Sleep Medicine (WPI-II

Published: March 2016


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The role of endothelin (ET)(A)-ET(B) receptor cross-talk in limiting the ET(A) receptor antagonist inhibition of ET-1 constriction is revealed by the partial or complete dependency of the ET(A) receptor antagonist inhibition on functional removal of the ET(B) receptor. Although functional removal of the ET(B) receptor is generally accomplished with ET(B) receptor antagonist, a novel approach using rats containing a naturally occurring deletion mutation in the ET(B) receptor [rescued "spotting lethal" (sl) rats; ET(B)(sl/sl)] demonstrated increased ET(A) receptor antagonist inhibition of ET-1 constriction in vena cava. We investigated whether this deletion mutation was also sufficient to remove the ET(B) receptor dependency of the ET(A) receptor antagonist inhibition of ET-1 constriction in the basilar artery. Consistent with previous reports, ET-1 plasma levels were elevated in ET(B)(sl/sl) as compared with ET(B)(+/+) rats. ET(B) receptor antagonist failed to relax the ET-1 constricted basilar artery from ET(B)(+/+) and ET(B)(sl/sl) rats. Relaxation to combined ET(A) and ET(B) receptor antagonist was greater than relaxation to ET(A) receptor antagonist in the basilar artery from ET(B)(+/+) and, unexpectedly, ET(B)(sl/sl) rats. These findings confirm the presence of ET(A)-ET(B) receptor cross-talk in the basilar artery. We speculate that mutant ET(B) receptor expression produced by alternative splicing may be sufficient to allow cross-talk.

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000335DOI Listing

Publication Analysis

Top Keywords

etb receptor
36
receptor antagonist
32
basilar artery
20
eta receptor
20
receptor
17
antagonist inhibition
16
eta-etb receptor
12
receptor cross-talk
12
inhibition et-1
12
et-1 constriction
12

Similar Publications

Inflammation is increasingly recognized as a risk factor for psychiatric disorders. Animal models of stress and stress-related disorders are associated with blood neutrophilia. The mechanistic relevance of this to symptoms or behavior is unclear.

View Article and Find Full Text PDF

Aprocitentan: a new horizon in the treatment of hypertension.

Expert Opin Pharmacother

August 2025

Department of Medicine, McGill University, Quebec, Canada.

Introduction: There has been a lack of novel medication classes approved for reducing blood pressure (BP) in hypertensive patients. Endothelins, powerful vasoconstricting peptides, have been at the forefront of experimental hypertension research since they were discovered in 1988. The recent PRECISION trial demonstrated the efficacy of aprocitentan, a novel endothelin receptor antagonist, in lowering blood pressure in patients with resistant hypertension (RH).

View Article and Find Full Text PDF

The endothelial glycocalyx (GCX) plays a crucial role in vascular health and integrity and influences many biochemical activities through mechanotransduction, in which heparan sulfate (HS) plays a major role. Endothelin-1 (ET-1) is a potent vasoregulator that binds to the endothelin B receptor (ETB) on endothelial cells (ECs), stimulating vasodilation, and to the endothelin A receptor on smooth muscle cells, stimulating vasoconstriction. While the shear stress (SS) dependence of ET-1 and HS is well documented, there is limited research documenting the SS dependence of the ETB.

View Article and Find Full Text PDF

GKB202 suppresses endothelin-1/ERK signaling in pancreatic cancer cells: Potential implications for circulating tumor cell regulation.

Biomed Pharmacother

August 2025

Biotech Research Institute, Grape King Bio Ltd., Long Tan Dist., Taoyuan City 325, Taiwan; Institute of BioPharmaceutical Science, National Sun Yat-sen University, Kaohsiung 804, Taiwan; Institute of Food Science and Technology, National Taiwan University, Taipei 106, Taiwan. Electronic address: gkb

Circulating tumor cells (CTCs) play a key role in cancer metastasis. However, the complex tumor microenvironment means that targeting these cells therapeutically remains a major clinical challenge. The natural compound GKB202, derived from the mycelium of Antrodia cinnamomea, has been shown to possess anti-cancer properties.

View Article and Find Full Text PDF